Online inquiry

IVTScrip™ mRNA-Anti-CA9, WX-G250(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15757MR)

This product GTTS-WQ15757MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CA9 gene. The antibody can be applied in Renal cell carcinoma (RCC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001216.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 768
UniProt ID Q16790
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CA9, WX-G250(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ15757MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5700MR IVTScrip™ mRNA-Anti-CD3E&CEACAM5, CEA TCB(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CEA TCB
GTTS-WQ3025MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Anti-Beta7
GTTS-WQ12900MR IVTScrip™ mRNA-Anti-FZD10, OTSA101-DTPA(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA OTSA101-DTPA
GTTS-WQ6447MR IVTScrip™ mRNA-Anti-HA, CT-P23(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CT-P23
GTTS-WQ7836MR IVTScrip™ mRNA-Anti-RTN4, GSK-1223249(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GSK-1223249
GTTS-WQ119MR IVTScrip™ mRNA-Anti-EGFR, 11F8(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA 11F8
GTTS-WQ8090MR IVTScrip™ mRNA-Anti-C5, h5G1.1HuG2/G4(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA h5G1.1HuG2/G4
GTTS-WQ14923MR IVTScrip™ mRNA-Anti-stx1B, Shigamabs®(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA Shigamabs®
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW